Clinical Trials
Riverside is here for you during the COVID-19 outbreak.

For more information, please click here.

Astra Zeneca D3614C00001 - A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First-Line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer

 

This purpose of this research study is to find out if a new medication called capivasertib given with one of the standards of care paclitaxel will work more effectively than paclitaxel alone as first line treatment of locally advanced (inoperable) or metastatic triple negative breast cancer.

Principal Investigator

William W. MacLaughlin, MD

Contact

Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]

Locations

Peninsula Cancer Institute
12100 Warwick Blvd. Suite 201
Newport News, VA 23601

Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320

Status

Recruiting

Category

Oncology

Study #

NCT03997123